Citi Sticks to Its Buy Rating for ProKidney (PROK)
Citi analyst Yigal Nochomovitz maintained a Buy rating on ProKidney on September 3 and set a price target of $10.00. The company’s shares closed yesterday at $2.30.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Nochomovitz covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Arcturus Therapeutics, and ProKidney. According to TipRanks, Nochomovitz has an average return of 7.0% and a 43.35% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ProKidney with a $5.80 average price target.
PROK market cap is currently $676.8M and has a P/E ratio of -4.07.
Read More on PROK:
Disclaimer & DisclosureReport an Issue
- ProKidney: Hold Rating Amid Encouraging Developments and Cautious Outlook
- ProKidney Corp. Reports Q2 2025 Financial Results
- ProKidney reports Q2 EPS (13c), consensus (14c)
- Prokidney Corp options imply 15.7% move in share price post-earnings
- Prokidney Corp options imply 13.0% move in share price post-earnings
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.